中华肝脏病杂志最新文献

{"title":"[A case report of mild hereditary hemochromatosis caused by HAMP gene mutation].","authors":"Z Wang, W Hou, H Zheng","doi":"10.3760/cma.j.cn501113-20240724-00345","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240724-00345","url":null,"abstract":"<p><p>The incidence of juvenile Hereditary Hemochromatosis caused by HAMP gene mutation is low, which is rarely reported in China. This patient took abnormal liver function as the first symptom, and was finally diagnosed by genetic testing and hepatic histopathology, and treated by venous bloodletting.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on the mechanism of Fuzheng Huayu formula against biliary fibrosis in mice].","authors":"Z Zhang, Y Liang, E Q Tang, X X Zhou, Y H Hu, G F Chen, W Liu, Y P Mu, P Liu, J M Chen","doi":"10.3760/cma.j.cn501113-20240815-00375","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240815-00375","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effect and mechanisms of Fuzheng huayu formula (FZHY) on biliary fibrosis in mice. <b>Methods:</b> <i>Mdr2</i> gene knowout (<i>Mdr2</i>^-/-) mice were randomly divided into model group, FZHY-treated group and obeticholic acid (OCA)-treated group. Wide type C57BL/6J (WT) mice of the same age were used as the control group. <i>Mdr2</i>^-/- mice were treated with the corresponding drugs by gavage from the first day of the 9^th week old. The WT and model groups were given 0.3% sodium carboxymethyl cellulose by gavage, and the mice were sacrificed at the end of 12^th week old. The activities of serum alkaline phosphatase (ALP) and alanine aminotransferase (ALT) were detected by high-speed biochemical analyzer. H&E staining and sirius red staining were used to observe the pathological changes of liver tissues. The hepatic hydroxyproline content was determined. The hepatic expressions of Col-Ⅰ and α-SMA, ductular reaction markers Epcam, CK7, CK19, and the expression of Pcna, Mki67 and Ccnd1; as well as the expression of inflammatory cytokines Ccl2, Ccl5, Tnf-α, Il10 and Cxcl4 were detected by immunohistochemical staining, western blot and qRT-PCR, respectively. Furthermore, the expression of PPARα and the phosphorylation NF-κB were detected by western blot. <b>Results:</b> Compared with WT mice, the serum ALT and ALP activities of <i>Mdr2</i>^-/- mice were significantly increased (<i>P</i><0.001). The percentage of SR positive stained area and hepatic Hyp content were significantly increased (<i>P</i><0.01). The hepatic expression of Col-Ⅰ and α-SMA; Epcam, CK7, CK19, Pcna, Mki67 and Ccnd1; Ccl2, Ccl5, Tnf-α, Il10 and Cxcl4 were significantly increased (<i>P</i><0.01). However, both FZHY and OCA significantly reversed the elevation of these aforementioned indicators (<i>P</i><0.05; <i>P</i><0.01). Further study showed that the hepatic expression of PPARα in <i>Mdr2</i>^-/- mice was significantly lower than that of WT mice, however the phosphorylation of NF-κB was significantly enhanced (<i>P</i><0.01). The expression of PPARα in liver tissues of FZHY mice was significantly increased (<i>P</i><0.05), and the NF-κB phosphorylation was significantly inhibited compared with <i>Mdr2</i>^-/- mice (<i>P</i><0.05). <b>Conclusion:</b> FZHY significantly ameliorated liver fibrosis, ductular reaction and inflammation in <i>Mdr2</i>^-/- spontaneous biliary fibrosis mice, and its mechanism was related to the regulation of PPARα/NF-κB pathway.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The nomogram model and its value study of Gd-EOB-DTPA enhanced MRI for preoperative diagnosis of proliferative hepatocellular carcinoma].","authors":"F X Chen, D J Guo, Y Xu, J Cheng, Y M Li, G L Chen, X M Li","doi":"10.3760/cma.j.cn501113-20240509-00246","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240509-00246","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To develop a nomogram model for preoperative diagnosis of proliferative hepatocellular carcinoma(HCC) based on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) enhanced magnetic resonance imaging (MRI), and to explore its clinical value. &lt;b&gt;Methods:&lt;/b&gt; MRI and clinical pathological data of patients confirmed by pathology as proliferative HCC (178 cases) and non-proliferative HCC (378 cases) between September 2017 and November 2022 who underwent preoperative Gd-EOB-DTPA enhanced MRI scans were retrospectively collected. The MRI features and clinical pathological characteristics of proliferative and non-proliferative HCC were evaluated. Multivariable logistic regression analysis was utilized to identify independent predictive factors for proliferative HCC, the R software was used to construct the nomogram prediction model, and its diagnostic performance was evaluated through receiver operating characteristic (ROC) curve. The calibration curve and decision curve analysis (DCA) were drawn to evaluate the calibration performance and clinical application value of the nomogram model. The optimal cut-off value was selected by calculating the Youden index to distinguish high risk and low risk. Kaplan-Meier survival curve was used to analyze the survival prognosis of proliferative and non-proliferative HCC, and log-rank test was used for comparison. &lt;b&gt;Results:&lt;/b&gt; There were significant differences in AFP level(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=17.244, &lt;i&gt;P&lt;/i&gt;&lt;0.001), morphology of tumor(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=13.669, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intertumoral fat(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=10.495, &lt;i&gt;P&lt;/i&gt;=0.001), arterial phase peritumoral enhancement(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=37.662, &lt;i&gt;P&lt;/i&gt;&lt;0.001), tumor capsule(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=23.961, &lt;i&gt;P&lt;/i&gt;&lt;0.001), substantial intratumoral necrosis(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=77.184, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral hemorrhage(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=4.892, &lt;i&gt;P&lt;/i&gt;=0.027), peritumoral hypointense in hepatobiliary phase(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=47.675, &lt;i&gt;P&lt;/i&gt;&lt;0.001), rim arterial phase hyperenhancement(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=115.976, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral artery(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=15.528, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and venous tumor thrombus(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=10.532, &lt;i&gt;P&lt;/i&gt;=0.001) between proliferative and non-proliferative HCC groups. Multivariate Logistic regression analysis showed that AFP&gt;200 ng/ml(&lt;i&gt;OR&lt;/i&gt;=0.640, &lt;i&gt;P&lt;/i&gt;=0.044), no intertumoral fat(&lt;i&gt;OR&lt;/i&gt;=1.947, &lt;i&gt;P&lt;/i&gt;=0.033), substantial intratumoral necrosis(&lt;i&gt;OR&lt;/i&gt;=0.480, &lt;i&gt;P&lt;/i&gt;=0.003), peritumoral hypointense in hepatobiliary phase(&lt;i&gt;OR&lt;/i&gt;=0.432, &lt;i&gt;P&lt;/i&gt;=0.001), and rim arterial phase hyperenhancement(&lt;i&gt;OR&lt;/i&gt;=0.180, &lt;i&gt;P&lt;/i&gt;&lt;0.001) were independent predictors of preoperative diagnosis of proliferative HCC. Based on the independent predictors, a nomogram model for preoperative prediction of proliferative HCC was established. The area under the ROC curve of the model for predicting proliferative HCC was 0.772 (95%&lt;i&gt;CI&lt;/i&gt;: 0.735～0.807),","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[An excerpt for the management of congenital portosystemic shunts and their complications: EASL expert consensus (2023)].","authors":"N Zhang, G H Han","doi":"10.3760/cma.j.cn501113-20240708-00317","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240708-00317","url":null,"abstract":"<p><p>This article is an excerpt from the Expert Management of Congenital Portosystemic Shunts and Their Complications, which was published by the European Association for the Study of the Liver (EASL). Some of the most challenging systemic complications that often associated with congenital portosystemic shunts (CPSS) are liver nodules, pulmonary hypertension, endocrine abnormalities, and neurocognitive dysfunction. This article mainly provides expert clinical guidance for the management of liver nodules, pulmonary hypertension, and endocrine abnormalities, along with recommendations for shunt closure and follow-up.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"965-969"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on the role and mechanism of PANoptosis in liver diseases].","authors":"L Y Miao, X Wang, Y Y Han","doi":"10.3760/cma.j.cn501113-20240122-00048","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240122-00048","url":null,"abstract":"<p><p>Pyroptosis, apoptosis, and necroptosis are three key types of pathways in programmed cell death (PCD). Studies have found a wide range of cross-talk between the three types of pathways, leading to the proposal of the concept of PANoptosis, or the inflammatory PCD pathway regulated by the PANoptosome complex, which has key features of pyroptosis, apoptosis, and/or necroptosis that cannot be explained by any of these single pathways. A growing number of studies have discovered that PANoptosis is involved in many liver-related disease processes, including liver cancer, metabolic-associated fatty liver disease, liver failure, fulminant viral hepatitis, and others. Therefore, this paper reviews the potential mechanism and role of PANoptosis in order to provide directions for studying the pathogenesis and potential therapeutic strategies for a variety of liver-related diseases.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"1047-1052"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of clinical, gene mutation characteristics, and treatment prognosis of type 2A hereditary hemochromatosis in the Chinese population].","authors":"W Zhang, Y M Li, A J Xu, X M Wang, Y Wang, W J Duan, X Y Zhao, H X Xu, J P Jiang, W Jiang, J Huang, X J Ou","doi":"10.3760/cma.j.cn501113-20231207-00271","DOIUrl":"10.3760/cma.j.cn501113-20231207-00271","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the clinical, genetic mutation characteristics, and treatment prognosis of type 2A hereditary hemochromatosis (HH) in China. <b>Methods:</b> Peripheral blood samples and clinical data of patients with primary iron overload were collected through the China Registry of Genetic/Metabolic Liver Disease from June 2015 to November 2023. HH-related genes were detected by Sanger sequencing. Clinical characteristics and gene mutation characteristics of HH patients carrying HJV gene mutations were analyzed. <b>Results:</b> Among the 37 cases with primary iron overload, ten cases (27.0%, 10/37) had detectable HJV gene mutations, which included four homozygous mutations, five compound heterozygous mutations, and one monoheterozygous mutation. p.Q6H and p.C321X (80.0%, 8/10) were the most common mutated sites. The average age of onset was 30.7±14.7 years. The age of diagnosis was 35.7±16.2 years, with male-to-female ratio of 7:3. Ferritin and transferrin saturation were (5 267±905) ng/ml, and 94.3%±1.2%, respectively. Magnetic resonance imaging showed iron overload in the liver, pancreas, and myocardium. Liver biopsy showed diffuse iron deposition within hepatocytes. All ten cases had elevated transaminases; one case (1/10, 10.0%) had liver cirrhosis; four cases (4/10, 40.0%) had heart failure and arrhythmia; five cases (5/10, 50.0%) had diabetes; six cases (6/10, 60.0%) had hypogonadism; six cases (6/10, 60.0%) had skin pigmentation; and six cases (6/10, 60.0%) had fatigue symptoms. All six cases underwent bloodletting therapy, and ferritin levels dropped to about 100 ng/ml. Two cases of oral administration of the iron chelator deferasirox did not meet the ferritin level standard, and one case died from acute heart failure following a confirmed diagnosis during hospitalization. <b>Conclusion:</b> The HJV gene may be one of the main pathogenic genes of HH in China. The p.Q6H and p.C321X mutations were one of the hotspot mutations. The onset age of HJV gene-related HH was between 20 and 30 years old, and their condition was severe. Therefore, early bloodletting treatment can have a favorable outcome.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"1013-1018"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Role of metabolic reprogramming-mediated hepatic stellate cell activation in the pathogenesis of hepatic fibrosis].","authors":"Y Xiao, Z N Wu, J Lu, Y D Wang","doi":"10.3760/cma.j.cn501113-20240223-00088","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240223-00088","url":null,"abstract":"<p><p>The activation of hepatic stellate cells (HSCs) and excessive deposition of extracellular matrix are the keys to the occurrence and development of liver fibrosis. Metabolic reprogramming supports the activation process of HSCs, which requires substantial energy to meet the corresponding energy requirements for liver fibrosis formation. This review focuses on the effect of metabolomic changes characterized by metabolic reprogramming on HSC activation and summarizes the characteristics of HSC energy metabolism reprogramming during the formation of liver fibrosis, with the aim to summarize research evidence for exploring the mechanism and developing strategies for the prevention and treatment of liver fibrosis.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"1053-1056"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Research and Application Progress of Heterologous Liver Transplantation].","authors":"Y Xie, D Wang, W T Jiang","doi":"10.3760/cma.j.cn501113-20240528-00270","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240528-00270","url":null,"abstract":"<p><p>Liver transplantation is an effective treatment for various end-stage liver diseases, and the shortage of donor livers is one of the main obstacles affecting the development of liver transplantation. Xenotransplantation holds promise as a potential solution to the organ shortage. By using gene-editing technology to modify animal genes, their physiological compatibility with humans can be improved. Combining this with new immunosuppressive drugs can reduce the occurrence of rejection, thereby increasing the survival time of the graft. Due to the more complex structure and physiological functions of the liver, inter-species incompatibility is more pronounced in liver xenotransplantation compared to heart or kidney. The molecular mechanisms related to xenograft rejection and coagulation disorders post-operation require further research. This article reviews the latest research progress domestically and internationally, the historical development of liver xenotransplantation, the main current challenges, and clinical applications, aiming to enhance clinicians' understanding of liver xenotransplantation.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Risk factors for intrahepatic venovenous shunt in patients with cirrhosis and its impact on hepatic venous pressure gradient].","authors":"L Z Ding, Z H Cai, J Q Xiao, M Zhang, F Zhang, Y Z Zhuge","doi":"10.3760/cma.j.cn501113-20231229-00308","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20231229-00308","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the factors affecting the incidence of intrahepatic venovenous shunt (IVVS) in patients with cirrhosis and its impact on hepatic venous pressure gradient (HVPG). <b>Methods:</b> A retrospective analysis was performed on the data of patients with liver cirrhosis who received HVPG measurement in Nanjing Drum Tower Hospital from April 2013 to March 2022. Univariate and multivariate regression analyses were used to investigate the incidence rate and risk factors of IVVS and its impact on HVPG. The <i>t</i>-test and rank-sum test were used for the measurement data, and the <i>χ</i>² test was used for the count data. <b>Results:</b> A total of 242 cases with cirrhosis were included in the statistical analysis, including 54 (22.3%) with IVVS and 188 (77.7%) without IVVS. There was a statistically significant difference (<i>P</i><0.05) in prothrombin time (PT), HVPG, and splenectomy history between the two groups of patients' baseline data (all <i>P</i><0.05). The multiple logistic regression analysis results showed that PT was an independent risk factor for the occurrence of IVVS (<i>P</i><0.05), and patients combined with IVVS had lower HVPG values [(17.58±5.57) mmHg vs. (11.92±5.38) mmHg, 1 mmHg=0.133 kPa; <i>t</i>=6.623, <i>P</i><0.001]. <b>Conclusions:</b> Patients with liver cirrhosis have a high incidence rate of IVVS, which is closely associated with a low prothrombin time. Additionally, patients combined with IVVS have low HVPG values, which affect its accuracy.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"984-988"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of the clinical characteristics of HBeAg-negative chronic HBV infection in indeterminate phase with a low viral load].","authors":"L L Zhou, X X Bai, B Dong, J J Xin, G H Xu, N Liu","doi":"10.3760/cma.j.cn501113-20231028-00158","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20231028-00158","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To analyze the clinical characteristics of HBeAg-negative chronic hepatitis B virus (HBV) infection in indeterminate phase with a low viral load. &lt;b&gt;Methods:&lt;/b&gt; One hundred and thirty-nine cases with persistent normal alanine aminotransferase (ALT) and HBeAg-negative chronic HBV infection with low viral load who visited the Department of Infectious Diseases of the Affiliated Hospital of Yan'an University from September 2013 to July 2021 were retrospectively collected. Patients were divided into low hepatitis B surface antigen (HBsAg) group (&lt;i&gt;n&lt;/i&gt;=59) and high HBsAg group (&lt;i&gt;n&lt;/i&gt;=80) according to the baseline hepatitis B surface antigen (HBsAg) level. The changes of various indicators at baseline and follow-up endpoints were analyzed between the two groups. The rate of HBsAg decrease ≥0.5 log&lt;sub&gt;10&lt;/sub&gt;IU/ml, HBV DNA negative conversion rate, ALT persistently normal rate, and liver stiffness measurement (LSM) persistently normal rate at the end of the follow-up were compared. The &lt;i&gt;t&lt;/i&gt;-test, or non-parametric Mann-Whitney &lt;i&gt;U&lt;/i&gt; test, and Wilcoxon signed rank test were used for comparison of continuous data between the two groups. The &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test, or Fisher's exact probability method, was used for comparing count data between the two groups. &lt;b&gt;Results:&lt;/b&gt; There were statistically significant differences in age, gender, and HBsAg at baseline, but there was no statistically significant difference in terms of family history of hepatitis B, follow-up time, anti-HBe, anti-HBc, HBV DNA, ALT, aspartate aminotransferase (AST), albumin (Alb), and LSM between the two groups. There were statistically significant differences in HBsAg, anti-HBc, and ALT levels before and after follow-up in the low HBsAg group, but no statistically significant differences in anti-HBe, HBV DNA, AST, Alb, and LSM levels. There were statistically significant differences in HBsAg and anti-HBc before and after follow-up in the high HBsAg group, but no statistically significant differences in anti-HBe, HBV DNA, ALT, AST, Alb, and LSM. A liver biopsy was performed in 66 patients during follow-up, and 27.27% of the patients had moderate liver damage. In the low HBsAg group, 45.76% of patients had a HBsAg decrease rate of ≥0.5 log&lt;sub&gt;10&lt;/sub&gt;IU/ml, 10.17% of patients had HBV DNA negative conversion, 88.14% of patients had a persistently normal ALT, and 96.61% of patients had a persistently normal LSM at the end of follow-up. In the high HBsAg group, 3.75% of patients had a HBsAg decrease of ≥0.5 log&lt;sub&gt;10&lt;/sub&gt;IU/ml, no patient had a HBV DNA negative conversion, 90% of patients had a persistently normal ALT, and 98.75% of patients had a persistently normal LSM. There were statistically significant differences in the HBsAg decrease rate (45.76% vs. 3.75%, &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=32.975, &lt;i&gt;P&lt;/i&gt;＜0.001) and HBV DNA negative conversion rate (10.17% vs. 0, &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=6.219, &lt;i&gt;P&lt;/i&gt;=0.013) between the two groups at the end of fol","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"970-975"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}